Lee, H., Chen, S., Liu, J., Li, P., Wu, L., Chang, S., . . . See, L. (2020). Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Cardiovasc Diabetol.
Chicago-стиль цитированияLee, Hsin-Fu, et al. "Major Adverse Cardiovascular and Limb Events in Patients With Diabetes and Concomitant Peripheral Artery Disease Treated With Sodium Glucose Cotransporter 2 Inhibitor Versus Dipeptidyl Peptidase-4 Inhibitor." Cardiovasc Diabetol 2020.
MLA-цитированиеLee, Hsin-Fu, et al. "Major Adverse Cardiovascular and Limb Events in Patients With Diabetes and Concomitant Peripheral Artery Disease Treated With Sodium Glucose Cotransporter 2 Inhibitor Versus Dipeptidyl Peptidase-4 Inhibitor." Cardiovasc Diabetol 2020.